Ontak Related Published Studies
Well-designed clinical trials related to Ontak (Denileukin Diftitox)
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. [2010.04.10]
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. [2009.07.16]
Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). [2002.03]
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. [2001.01.15]
Well-designed clinical trials possibly related to Ontak (Denileukin Diftitox)
Graft-versus-host disease treatment: predictors of survival. [2010.12]
Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. [1998.06]
Other research related to Ontak (Denileukin Diftitox)
NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. [2011.03.15]
A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC). [2010.09]
Denileukin diftitox: a novel immunotoxin. [2009.11]
A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. [2009.06]
Optimizing denileukin diftitox (Ontak) therapy. [2008.08]
De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission. [2008.07]
Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis. [2008.07]
Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin diftitox. [2008.02]
Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497. [2007.12]
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. [2007.11.01]
Denileukin diftitox as novel targeted therapy for lymphoid malignancies. [2007.09]
Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma. [2007.09]
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. [2007.08]
Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. [2007.07]
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. [2007.02]
Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. [2007.01]
Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox. [2006.11]
Denileukin diftitox as prophylaxis against graft-versus-host disease in the canine hematopoietic cell transplantation model. [2006.09]
Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. [2006.06]
Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. [2006.05.15]
Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene. [2006.05]
Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case. [2006.05]
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. [2006.03]
Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma. [2005.12]
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. [2005.11]
A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. [2005.07.15]
Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. [2005.03]
Denileukin diftitox: a concise clinical review. [2005.02]
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. [2004.10.15]
Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. [2004.08.15]
Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma. [2004.04]
Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. [2003.12]
A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. [2003.09.01]
Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy. [2003.04]
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia. [2003.02]
A complete and durable response to denileukin diftitox in a patient with mycosis fungoides. [2003.02]
Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. [2002.08.15]
Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). [2002.01]
A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. [2001.12]
Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. [2001.03]
Denileukin diftitox. [2000.11]
Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. [2000.11]
DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications. [2000.11]
DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date. [2000.11]
DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. [2000.11]
DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. [2000.09]
Denileukin diftitox. [2000.01]
Other possibly related research studies
[Novel treatment modalities in cutaneous T cell lymphoma. Biologic response modifiers] [2005.06.05]
Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. [2004.12]
Novel strategies for steroid-refractory acute graft-versus-host disease. [2005.01]
Recombinant immunotoxins for the treatment of haematological malignancies. [2004.07]
Cutaneous T-cell lymphoma: a paradigm for biological therapies. [2004.09]
Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches. [2003]
Bexarotene: a clinical review. [2004.04]
Novel therapies for chronic lymphocytic leukemia. [2004.06]
Management of mycosis fungoides: Part 2. Treatment. [2003.10]
Diphtheria toxin conjugate therapy of cancer. [2002]
Recombinant toxins for the treatment of cancer. [2003.02]
Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma. [2002]
Recombinantly engineered human proteins: transforming the treatment of psoriasis. [2002.11]
Toxin-labeled monoclonal antibodies. [2001.12]
Cutaneous T-cell lymphoma. New immunomodulators. [2001.10]
Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. [2001.09]
Therapeutic advances in biological response modifiers in the treatment of cutaneous T-cell lymphoma. [2001]
Immunotoxins. [2000.09]
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. [1998.07]
Immunotherapy of experimental autoimmune myasthenia gravis: selective effects of CTLA4Ig and synergistic combination with an IL2-diphtheria toxin fusion protein. [1998.07.01]
DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. [1998.05]
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. [1998.01.15]
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. [1997.01]
Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy. [1995.12]
Targeting diphtheria toxin to growth factor receptors. [1995.10]
Mycosis fungoides and the Sezary syndrome. [2004.09]
Current management strategies for cutaneous T-cell lymphoma. [2004.05]
Treatment of T-cell non-Hodgkin's lymphoma. [2004.08]
Management of the primary cutaneous lymphomas. [2003.11]
Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. [2002.10]
Gateways to Clinical Trials. June 2002. [2002.06]
Treatment of cutaneous T cell lymphoma: current status and future directions. [2002]
Monoclonal antibody therapy for lymphoma: an update. [2001.03]
Monoclonal antibody therapies for lymphomas. [2000.09]
Immunomodulatory effects of rexinoids. [2006.02]
Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. [2005.12]
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. [2005.12]
Immunotherapy as part of a multidisciplinary approach to melanoma treatment. [2006.01.01]
Primary CD20+CD10+CD8+ T-cell lymphoma of the skin with IgH and TCR beta gene rearrangement. [2006.07]
Bexarotene in the treatment of cutaneous T-cell lymphoma. [2006.05]
Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL). [2006.02]
Update on the management of acute graft-versus-host disease. [2006.03]
Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. [2006.12]
Immunotoxins in the treatment of hematologic malignancies. [2006.10]
Management of refractory early-stage cutaneous T-cell lymphoma. [2006]
Novel strategies for the treatment and diagnosis of graft-versus-host-disease. [2007.03]
Treatment of cutaneous T-cell lymphoma/mycosis fungoides. [2006.12]
Optimal combination with PUVA: rationale and clinical trial update. [2007.02]
|
